Zevra Therapeutics (ZVRA) Stock Price, News & Analysis

Company Overview

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Key Stats

• Today's Range: $8.32 to $9.17
• 50-Day Range: $6.85 to $9.03
• 52-Week Range: $4.18 to $9.21
• Volume: 1.37 million shs
• Average Volume: 595,881 shs
• Market Capitalization: $453.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.00
• Consensus Rating: Buy

Zevra Therapeutics Stock Analysis - MarketRank™

Zevra Therapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 344th out of 970 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Zevra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Zevra Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Zevra Therapeutics are expected to grow in the coming year, from ($1.92) to ($0.44) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zevra Therapeutics is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zevra Therapeutics is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Zevra Therapeutics has a P/B Ratio of 6.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.53% of the float of Zevra Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Zevra Therapeutics has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in Zevra Therapeutics has recently decreased by 21.20%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zevra Therapeutics does not currently pay a dividend.

Dividend Growth

Zevra Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.53% of the float of Zevra Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Zevra Therapeutics has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in Zevra Therapeutics has recently decreased by 21.20%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.47

News Sentiment

Zevra Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 36 news articles for Zevra Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 4 people have searched for ZVRA on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Zevra Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -91% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Zevra Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,960.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 2.40% of the stock of Zevra Therapeutics is held by insiders.

Percentage Held by Institutions

Only 35.03% of the stock of Zevra Therapeutics is held by institutions.

ZVRA Stock Analysis - Frequently Asked Questions

How have ZVRA shares performed this year?

Zevra Therapeutics' stock was trading at $6.55 at the start of the year. Since then, ZVRA shares have increased by 31.6% and is now trading at $8.62.
View the best growth stocks for 2024 here.

How were Zevra Therapeutics' earnings last quarter?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) posted its earnings results on Tuesday, November, 12th. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by $0.25. The firm earned $3.70 million during the quarter, compared to analyst estimates of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative trailing twelve-month return on equity of 159.54%.

Who are Zevra Therapeutics' major shareholders?

Top institutional investors of Zevra Therapeutics include FMR LLC (4.40%), Geode Capital Management LLC (1.98%), State Street Corp (1.47%) and Stonepine Capital Management LLC (1.33%). Insiders that own company stock include John B Bode, Thomas Anderson, Matthew R Plooster, Timothy J Sangiovanni, Joshua Schafer, Corey Michael Watton and Tamara A Seymour.
View institutional ownership trends.

How do I buy shares of Zevra Therapeutics?

Shares of ZVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Zevra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zevra Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Invesco QQQ (QQQ) and Tesla (TSLA).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 11/17/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/27/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ZVRA
• CUSIP: N/A
• CIK: 1434647
• Web: www.kempharm.com
• Phone: (321) 939-3416
• Fax: 319-665-2577
• Employees: 65
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $21.00
• High Stock Price Target: $25.00
• Low Stock Price Target: $17.00
• Potential Upside/Downside: +143.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-46,050,000.00
• Net Margins: -342.63%
• Pretax Margin: -361.75%
• Return on Equity: -159.54%
• Return on Assets: -51.50%

Debt

• Debt-to-Equity Ratio: 0.84
• Current Ratio: 2.88
• Quick Ratio: 2.00

Sales & Book Value

• Annual Sales: $27.46 million
• Price / Sales: 16.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.33 per share
• Price / Book: 6.48

Miscellaneous

• Outstanding Shares: 52,620,000
• Free Float: 51,355,000
• Market Cap: $453.58 million
• Optionable: Optionable
• Beta: 1.93